Brief: Can-Fite’S Phase III Psoriasis Study Data Expected Q2 2022
08/03/2022 12:57
March 8 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE’S PHASE III PSORIASIS STUDY DATA EXPECTED Q2 2022
Source text for Eikon: ID:nBw8btsdna
Further company coverage: CANF.TA
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage